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INTRODUCTION
The  diagnosis  of  prostatic  adenocarcinoma  particularly  when 
present in small amounts, is often challenging. Before making a diagnosis 
of  carcinoma  it  is  prudent  for  the  pathologist  to  consider  the  various 
benign entities that can mimic prostatic adenocarcinoma.
A  valuable  method  of  classifying  benign  mimickers  is  in 
relationship to major growth patterns depicted in the Gleason diagram. 
The four major  patterns are small  gland,  large gland fused gland, and 
solid. Most of the mimickers fit in the small gland type and common ones 
giving  rise  to  false  positive  diagnosis  are  small  acinar  atrophy,  post 
atrophic  hyperplasia,  atypical  adenomatous  hyperplasia  and  seminal 
vesicle.
Other  normal  structures  like  cowper’s  gland  verumontanum 
mucosal glands,   paraganglionic tissue and mesonephric glands can be 
confused  with  adenocarcinoma.  Also  metaplastic  and  hyperplastic 
processes in the prostate may possibly be confused with adenocarcinoma.
Moreover, inflammatory processes like granulomatous prostatitis, 
Xanthoma, and malakoplakia may replicate high-grade adenocarcinoma, 
clear cell adernocarcinoma in particular.
Atypical adenomatous hyperplasia (adenosis), a alleged precursor 
of adenocarcinoma has similar features with low grade adenocarcinoma 
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and  might  cause  problems  in  differential  diagnosis  in  needle  biopsy 
setting.  At  the other  end,  poorly  differentiated  adenocarcinoma of  the 
prostate  may  be  difficult  to  distinguish  from inflammatory  infiltrates, 
metastatic  carcinoma and TCC involving the prostate  and can lead to 
false negative cancer interpretation.  
The  Pathologist’s  familiarity  of  the  vast  collection  of  benign 
mimickers  is  important  in the systematic  approach to the diagnosis  of 
prostatic  adenocarcinoma.  Awareness  of  these  patterns  on  light 
microscopy coupled with the cautious use of immunohistochemistry will 
guide to a correct diagnosis and avoid a false-positive and false negative 
cancer interpretation.
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AIMS AND OBJECTIVES OF THE STUDY
1. To define, list and study the clinical and histopathological features 
of mimics of    prostatic adenocarcinoma.
2. To  differentiate  histopathologically  between  mimics  and 
adenocarcinoma.
3. To define the role of immunohistochemical markers in differential 
diagnosis of adenocarcinoma and its mimics.
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REVIEW OF LITERATURE
ANATOMY
        The prostate is a sex related gland that belongs to male reproductive 
system, having the size of walnut and weighs up to 20 g. It is situated 
around the upper part of the urethra and lies with its superior surface (the 
base) immediately below the urinary bladder and its inferior surface (the 
apex) above the pelvic musculofascial floor. A thin layer of connective 
tissue  surrounds  the prostate.  The  Denonviler’s  fascia  seperates  its 
posterior surface from the rectum. The prostate is anteriorly fixed to the 
pubic  bone with the  help of  puboprostatic  ligaments  and held in  the 
dorsal vein plexus between these structures1,2,3.
        Mc Neal described the zonal anatomy of the prostate which includes 
the  peripheral,  transition  and  central  zone  representing  approximately 
65%, 10%and 25% respectively of the normal organ volume. This zonal 
anatomy is important is prostate pathology. Most of the cancers develop 
in the Peripheral zone (PZ) and benign hyperplasia mainly develops in 
the transition zone (TZ) of the prostate gland (Mc Neal 1988)
HISTOLOGY
          The prostate is composed of fibromuscular stroma and 30-50 
glands that empty its contents into the prostatic urethra. Two cell layers 
form the branching duct acinar system, the luminal columnar secretory 
4
cells and the basal cells2,3,4.The architectural structure and polarity of the 
glandular  cells  are  important  for  diagnosing  and  grading  prostatic 
carcinoma.
The prostate does not have a well-defined capsule  5, but the most 
peripheral layer of the fibromuscular stroma bordering on periprostatic 
fat, forms a  pseudocapsule. The  organ borders become very intricate at 
the base of the prostate, particularly at the junction with seminal vesicles, 
while  in  other  areas  prostatic  glands  reach  the  edge  of  the  prostate 
without  a  distinct  capsule,  leading to  difficulties  in  the  assessment  of 
extra prostatic extension. 
The  prostate  is  supplied  by  branches  from  the  inferior  vesical, 
internal pudendal artery and middle rectal arteries. It drains into internal 
vesical  and  internal  iliac  veins.  Lymphatics  from  the  prostate  drain 
chiefly into internal iliac, sacral and obturator nodes. The prostate has an 
abundant nerve supply from the inferior hypogastric plexus 6.
PHYSIOLOGY
The prostate gland secretes a milky, alkaline fluid into the urethra 
during  ejaculation.  The  prostate  fluid  is  a  semen  component  and 
represents one half to two thirds of ejaculate volume. It is slightly acidic 
(pH6.5)  and  contains  several  secretory  products  like  acid  phosphate, 
citrate,  zinc,  carbohydrates,  soluble  proteins,  electrolytes,  hormones, 
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lipids  and  growth  factors  7.  Among  them  is  prostate-specific  antigen 
(PSA),  which  proved  to  be  of  paramount  importance  for  diagnosing 
prostatic adenocarcinoma. PSA is a glycoprotein that has been recognized 
as a kallikerin like protease and its main role is to keep the semen liquid 8.
Although  prostate  specific  antigen  is  specific  for  prostatic 
epithelium, it is not a prostate cancer specific as it can be found elevated 
in many of the benign conditions that may affect the gland as well as in 
malignant lesions9. In addition some authors found correlation between 
patient’s age and PSA level10..  Kamal B, Ali G,Taha S. conducted a study 
in saudhi men and found that the PSA level increases with age and the 
mean values of total PSA were 0.87 for men in 40-49 years, 1.36 for men 
in 50-59 years, 1.81 for men in 60-69 years, 2.32 for men in 70-79 years 
and 2.36 for men in 80-89 years.
PSA is the now commonest initial assessment method used in the 
early detection and follow up of the prostate cancer. However its ability 
to distinguish among benign and malignant lesions is particularly poor in 
the intermediate range of 4.1and 10ng/ml.
ADENOCARCINOMA OF THE PROSTATE
Prostate cancer is the most common cancer in men accounting for 
33% of all  malignant  tumours  in  men and accounts  for  9% of  cancer 
death.  Excluding  skin  cancer,  prostate  cancer  is  the  most  commonly 
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diagnosed cancer among men in the US and the second most common 
cause of cancer related death among men11.
Age  is  the  most  important  risk  factor  for  prostate  cancer.  The 
incidence  rate  increases  in  men  until  about  age  70  and  decline 
thereafter11,12.  Carcinoma may arise in any zone of the prostate but the 
relative distribution is different in each zone: 68% of the carcinoma occur 
in the peripheral zone, 24% arise in the transition zone and 8% develops 
in the central zone13.
DIAGNOSIS OF MINIMAL ADENOCRCINOMA IN PROSTATE 
NEEDLE  BIOPSY14.
Algaba  et  al  defined  the  criteria  for  the  diagnosis  of  minimal 
prostatic  adenocarcinoma15.
MAJOR CRITERIA
• Architectural: Infiltrative small glands or cribriform glands too 
large or irregular to signify high grade PIN.
• Absence of basal cell layer
• Nuclear and nucleolar enlargement.
MINOR CRITERIA
• Intraluminal wispy blue mucin
• Pink amorphous secretions 
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• Mitosis
• Intraluminal crystalloids
• Adjoining  high-grade PIN
• Amphophilic cytoplasm.
• Nuclear hyperchromasia.
No single criterion, not even one of the major diagnostic criteria, is 
by  itself  diagnosis  of  malignancy.  Rather  consideration  of  the 
constellation of findings assist in arriving at a specific diagnosis.
DIFFERENTIAL  DIAGNOSIS  AND  MIMICS  OF 
ADENOCARCINOMA OF PROSTATE
A  PATTERN  BASED  APPROACH  TO  DIFFERENTIAL 
DIAGNOSIS
The utility of the famous Gleason diagram extends beyond its role 
as a Grading tool 16. Dr Donald F Gleason and members of the veteran’s 
administration  Cooperative  urological  Research  group.17 (VACURG) 
devised grading system of adenocarcinoma in 1960s and 1970s.
From 1960 to 1975 the VACURG examined roughly about 5000 
prostate cancer patients in prospective randomized clinical trials. One of 
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the major strength of the Gleason grading system is that it was tested in 
this large population, with long term follow-up17.
In the Gleason diagram, there are nine patterns which are clumped 
into  four  major  architectural  categories  for  discussion  of  differential 
diagnosis18
Major growth patterns of adenocarcinoma
Growth   pattern Gleason pattrrn Descriptions
1. Small gland
2. Large gland
3. Fused gland
4. Solid
1, 2, 3A, 3B
3A, 3C, 5A.
4A, 4B
5B
Tiny, small , medium 
separate acini
Simple, papillary, 
cribriform.
Coalescing acini, 
amphophilic or clear. 
(Hypernephroid)
Sheets, cords, single 
cells.
The leading pattern of adenocarcinoma is  small glandular pattern. 
Most of the benign mimickers come in the differential diagnosis of small 
gland adenocarcinoma.
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PROSTATIC INTRAEPITHELIAL NEOPLASIA
In 1986 Mc Neal & Bostwick, studied 100 specimens of prostatic 
adenocarcinoma  and  100  benign  prostates  obtained  at  autopsy.  They 
noticed  foci  of  PIN  in  82  prostates  with  carcinoma  and  43  benign 
prostates.  It  provided strong support  regarding the  status  of  PIN as  a 
precursor lesion.
CRITERIA FOR PROSTATIC INTRA EPITHELIAL NEOPLASIA
FEATURES LOW GRADE PIN HIGH GRADE PIN
A. Architectural 
features
Epithelial cell 
crowding with 
irregular spacing
similar to low 
grade,more crowding 
and stratification
B. cytological features
Nuclei Enlarged with 
considerable size 
variation
Enlarged with some 
size and shape 
variation
Chromatin Normal Increased in density 
and clumping
Nucleoli Rarely prominent Large and prominent, 
sometimes multiple
C. Associated features
Basal cell layer Intact May show disruption
Basement 
membrane
Intact Intact
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CLASSIICATION  OF  BENIGN  MIMICKERS  OF 
ADENOCARCINOMA
HISTOANATOMIC STRUCTURES
• Seminal vesicle/ejaculatory duct
• Cowper’s gland
• Paraganglion
• Verumontanum mucosal glands (hyperplasia)
• Mesonephric gland remanants
ATROPHY
• Simple (Lobular)
• Sclerotic
• Cystic
• Linear
• Post atrophic hyperplasia (partial atrophy)
INFLAMMATION
• Usual prostatitis with preservation artefacts
• Granulomatous prostatitis, non specific
• Xantho granulomatous prostatitis (xanthoma)
• Malakoplakia.
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REACTIVE ATYPIA
• Inflammatory
• Ischemic
• Radiation 
METAPLASIA
• Mucinous
• Nephrogenic (adenoma)
PROSTATIC HYPERPLASIA
• Basal cell hyperplasia
• Benign nodular hyperplasia, small gland pattern
• (clear cell) cribriform hyperplasia
• Sclerosing adenosis
• Atypical adenomatous hyperplasia.
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BENIGN MIMICKERS IN RELATION TO MAJOR GROWTH  
PATTERNS OF PROSTSTIC ADENOCARCINOMA
Small gland pattern
• Seminal vesicle
• Cowper’s gland
• Atrophy
• Post atrophic hyperplasia
• Reactive atypia
• Mucinous metaplasia
• Nephrogenic metaplasia
• Basal cell hyperplasia
• Benign nodular hyperplasia
• Sclerosing adenosis
• Verumontanum mucosal gland hyperplasia
• Mesonephric gland hyperplasia
• Atypical adenomatous hyperplasia.
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Large gland pattern
• Clear cell cribriform hyperplasia
• Reactive atypia
Fused gland pattern
• Paraganglioma 
• Xanthogranulomatous inflammation
• Malakoplakia 
Solid pattern
• Usual prostatitis with crush artefact
• Idiopathic granulomatous prostatitis
• Signet ring like changes in stromal cells and lymphocytes 
As  already  stated  nearly  all  benign  mimickers  come  in  the 
differential diagnosis of small gland pattern.    
SEMINAL VESICLE
Seminal  vesicle  tissue possibly present  in transurethral  resection 
specimens or in needle biopsies, generally unexpectedly. Sometimes they 
are specifically sampled.
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Jensen KM, Sonneland P. reviewed histologic specimens from 123 
consecutive patients undergoing transurethral resection of prostate for the 
existence of seminal vesicle tissue. The incidence was 23%.19
Arias-stella  J,  Takano-Manon  J  reviewed  264  prostatic  needle 
biopsy  specimen for the presence of seminal vesicle. The incidence was 
15%.20  They also described atypia in seminal vesicle epithelium in old 
age.
ATROPHY
In 1936, Moore et al21, studied 678 prostate gland specimens and 
published a detailed account of the histological  features of the normal 
gland  and  involutional  prostate  gland  .  He  suggested  atrophy  as  a 
physiological  and  age  related  phenomenon.  He  also  described  the 
presence of luminal acidophilic secretions in atrophy. Atrophy of prostate 
is a general process characteristically but not exclusively seen in older 
patients. In young adults it is usually admixed among areas of nodular 
hyperplasia.22
The term proliferative inflammatory atrophy was introduced by De 
Marzo  et  al.  23  to  designate  discrete  foci  of  proliferative  glandular 
epithelium which exhibits morphologic appearance of simple atrophy or 
post atrophic hyperplasia which occurs in association with inflammation. 
De Marzo et al.23 and Putzi suggested that post inflammatory atrophy may 
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indeed give rise to carcinoma directly or indirectly via development into 
HG-PIN.
But Athense Billis, Luis A Magna24 studied 100 prostate specimens 
from men older than 40 years and found that post inflammatory atrophy 
does not seem to be associated with histological carcinoma or LG-PIN.
POST ATROPHIC HYPERPLASIA
In  1936  Moore25 illustrated  and  published  post  atrophic 
hyperplasia, although he did not make any special reference to it in the 
text. This was followed by Totten et al in 1953, but they referred to this 
process as lobular hyperplasia.  The term post  atrophic hyperplasia and 
post  sclerotic  hyperplasia  were  coined  by  Frank  et  al  in  1954,  who 
proposed this lesion as a precursor to prostatic adenocarcinoma. But later 
studies  failed  to  establish  such  relationship  between  post  atrophic 
hyperplasia and prostatic adenocarcinoma.
In 1999 Mahul B.Amin, Phenoze Tamboli, Muralivarma and John 
R.Srigley26  studied  56  needle  biopsy  specimens  to  ascertain  the 
morphologic spectrum of post atrophic hyperplasia.  Age of the patient 
ranged from 49 to 85 years. Selection of  cases were restricted to those 
containing foci  of small  acinar proliferation atleast  some of which are 
suspicious  of  carcinoma.  In  this  study  prevalance  of  post  atrophic 
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hyperplasia presenting as small acinar proliferation in consecutive biopsy 
specimen was 3.6%.
ATYPICAL ADENOMATOUS HYPERPLASIA (ADENOSIS)
Atypical adenomatous hyperplasia is one more common mimicker 
of prostatic adenocarcinoma recognised on both biopsy and transurethral 
resectates. In 1986 Mc Neal27 referred atypical adenomatous hyperplasia 
(AAH)  as  a  possible  premalignant  proliferation,  most  probably  of 
carcinoma arising in the transition zone. In 2000, Kien, T.Mare  et al. 28 
reviewed  533 and 499 TURP specimens before and after the introduction 
of  PSA  screening  respectively.  They  suggested  the  possibility  of 
association  of  atypical  adenomatous  hyperplasia  with  low  grade 
carcinoma developing from transitional zone and association of PIN with 
carcinomas arising in non-transitional zone.
Atypical  adenomatous  hyperplasia  has  been  projected  as  a 
precursor  of  prostatic  adenocarcinoma  of  the  transitional  zone  for  the 
following reasons.
i. Age peak that precedes that of PCa.
ii. Increased incidence in association with PCa.
iii. Topographic relationship with small acinar PCa.
iv. Increased size of nucleus.
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iv. A proliferative index similar to that of small acinar PCa.
v. Occasional cases with genetic alterations.
The  term  ‘adenosis’  was  suggested  to  replace  atypical 
adenomatous hyperplasia. This has not been accepted and ‘atypical’ has 
been retained to indicate the unusual pattern of small acinar formations 
that characterize AAH.
Currently, the term atypical adenomatous hyperplasia is replaced 
by “Atypical small acinar proliferation” (ASAP).       
Previously  the  data  were  insufficient  to  conclude  atypical 
adenomatous  hyperplasia  as  a premalignant  lesion.  In  2005 Courtenay 
K.Moore et al. in their study of 1,188 cases selected 105 cases of which 
33 had HGPIN and 72 had ASAP.  They applied an extended biopsy 
scheme over  the patients  diagnosed with high grade PIN and atypical 
small  acinar  proliferation.  According  to  that  study  in  the  first  repeat 
biopsy, only 1 of 22 (4.5%) men with previous HG PIN had cancer while 
19 of 53 (36%) with a history of ASAP were found to have cancer.  In the 
second repeat biopsy, none of the 11 men previously diagnosed with HG 
PIN had cancer. But 3 of 19 (16%) men with ASAP had cancer.
Hence, they recommended that high-grade PIN does not warrant a 
repeat  biopsy  and  atypical  small  acinar  proliferation  continues  to  be 
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associated  with  a  high  risk  of  cancer  and  requires  atleast  one  repeat 
biopsy using extended biopsy scheme.
Ahmet  Midi,  Tulay  Tecimer,  Suhayala  Bozkurt29  reviewed  105 
radical  prostatectomy specimens and defined new histologic criteria to 
differentiate  AAH from prostatic  adenocarcinoma grade 1and 2.  They 
assesed  18  anatomical  and  structural  parameters  and 
immunohistochemistry with 34βE12-basal cell marker.  They concluded 
the lack of basal cells in adenocarcinoma and their occasional presence in 
AAH is the most important diagnostic criterion.
BASAL CELL HYPERPLASIA.
Basal cell hyperplasia was fairly a common lesion in hyperplastic 
prostates being examined by Young R.H. et al.30 in his studies. Basal cell 
hyperplasia  is   seen  in  the  transition  zone  typically  as  a  part  of  the 
continuum  of  benign  nodular  hyperplasia.  Recently  it  has  been 
recognised that basal cell hyperplasia might also involve the peripheral 
zone.
Phatarapon  Thorson,  et  al31 studied  the  existence  of  basal  cell 
hyperplasia in the peripheral zone of the prostate.    They reviewed series 
of  500  consecutive  needle  biopsies  and  26  radical  prostatectomy 
specimens.  The incidence of BCH in needle biopsy tissue was 10.2%. 
Usual basal cell hyperplasia was noticed in 8.2% of the 500 cases and 
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atypical  basal  cell  hyperplasia  was  2.0%.  84%  cases  of  basal  cell 
hyperplasia was associated with lymphocytic infiltration. 23% of whole 
prostate glands showed basal cell hyperplasia in peripheral zone.
Basal cell hyperplasia is easily separated from adenocarcinoma in 
majority  of  the  cases,  particularly  in  transurethral  resectate  and  open 
prostatectomy specimens. The nodular architecture, presence of ordinary 
nodular  hyperplasia,  lack  of  pleomorphism  and  absence  of  prominent 
nucleoli assist in separating this condition from carcinoma.  However it 
may  be  difficult  in  small  biopsies.  In  such  cases  the  recognition  of 
uniform cytological  and  nuclear  features  along  with  staining  for  high 
molecular  weight  keratin(34βE12) serve to seprate  this condition from 
adenocarcinoma.
CLEAR CELL CRIBRIFORM HYPERPLASIA
Clear cell cribriform hyperplasia of the prostste is a rare form of 
hyperplasia found in BPH. It  was recognised in 1980 by world health 
organisation. Gleason described the same lesion as florid benign papillary 
cribriform hyperplasia  in 1985.  The clear  cells  of  CCCH show strong 
immunoreactivity  with  prostate  specific  antigen  and  prostatic  acid 
posphatase. Cribriform hyperplasia is a mimicker of both prostatic intra 
epithelial neoplasia and cribriform adenocarcinoma. The difference relies 
mainly  on  the  identification  of   nodularity  in  the  low power,  cellular 
stroma, existence of basal cells and absence of cytologic atypia.
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SCLEROSING ADENOSIS 
Sclerosing  adenosis  is  a  prostatic  lesion  which  has  been  first 
reported by Chen A Schiff in 1983 as adenomatoid tumor of prostate due 
to  its  morphologic  resemblance  to  adenomatoid  tumor.   Young  and 
Clement introduced the term sclerosing adenosis in 1987 on the basis of 
histologic resemblance to sclerosing adenosis of the breast.
In  1991  Sakomoto  et  al.32 analyzed  263  specimens  of  prostate, 
found 5 cases of sclerosing adenosis with incidence of 1.9% which was 
found to be localised to the transition zone.  
Rafael J.Luque et al.33 described histological features of sclerosing 
adenosis of the prostate. They found a combination of histologic (mainly 
myxoid  cellular  stroma  and  double  layering  of  acinar  cells)  and 
immunohistochemical  features  demonstrating  a  continuous  basal  cell 
layer with myoepithelial differentiation to be diagnostic. 
MUCINOUS METAPLASIA
Mucinous metaplasia was studied by Frank et al.34 in 1964. About 
155 prostate  glands  were studied in which whole organ sections were 
stained for mucin. They described the presence of PAS and alcian blue 
positive goblet cells within the transitional epithelium of prostatic urethra 
and proximal prostatic ducts.
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Dikman  and  Toker  et  al.35 in  1973  noted  the  presence  of 
seromucinous glands in prostatic stroma. They concluded that the lesion 
was an ectopia of minor salivary glands.
In  1993  David  J.  Grignon  and  Frances  P.O Malley36 noted  tall 
columnar  mucin  secreting  cells  in  12  cases  of  benign  prostatic 
hyperplasia  out  of  1700  cases  in  a  three  year  study  and  stained 
histochemically  for  mucicarmine,  alcian  blue  and periodic  acid schiff. 
They documented the presence of acid mucin in the luminae of basal cell 
hyperplasia, post atrophic hyperplasia and also in some glands involved 
with  transitional  cell  metaplasia.  The  presence  of  acidic  mucin  in 
secretory  cells  in  benign  lesions  indicates   the  nonspecificity  of  this 
finding in the diagnosis of malignancy.
MESONEPHRIC GLAND HYPERPLASIA
Remnants of mesonephric glands are rarely identified in prostatic 
specimens.  In  a  series  of  700  transurethral  resectates,  0.6%  had 
mesonephric remnants37. Occasionally they may go through hyperplasia 
and possibly confused with adenocarcinoma. Two cases of mesonephric 
gland hyperplasia is identified by Gikas et al. in transurethral resection 
specimens that were diagnosed as adenocarcinoma and led to unnecessary 
radical prostatectomy38  in one case. Immunohistochemistry is helpful in 
such cases. The mesonephric glands stains negatively for PSA, PAP and 
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stain positively for HMWCK in contrary to adenocarcinoma which lacks 
basal cells.
VERUMONTANUM MUCOSAL GLAND HYPERPLASIA
Verumontanum mucosal gland hyperplasia is generally incidentally 
discovered  in  radical  prostatectomy  specimens39.  The  incidence  was 
found  to  be  14%  in  one  series  containing  30  radical  prostatectomy 
specimens. This process is hardly seen in needle biopsy specimens40. It is 
characterized  by  uniform  round  glands  which  are  closely  packed, 
containing numerous corpora  amylacea.
Basal cells are typically identified and there is no nuclear features 
of  malignancy.  Specifically,  prominent  nucleoli  are  not  seen.The 
existence of lipofuscin pigment in the cytoplasm of glandular cells is also 
an important diagnostic clue.
The prominent  basal cells  and corpora amylacea,  the absence of 
nuclear  atypia  and  suburethral  location  helps  in  differentiating  from 
adenocarcinoma.
NEPHROGENIC METAPLASIA (ADENOMA)
The  nephrogenic  adenoma  (NA),  a  lesion  of  suspected  renal 
tubular origin, is seen in different sites within the urinary system which 
includes the renal pelvis, ureters, urinary bladder ( common location), and 
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prostatic urethra. It is mistaken for prostatic adenocarcinoma especially 
when  it  is  located  in  the  prostatic  urethra.  Histologically  papillary 
structures,  small,  or  dilated  tubules  lined  by  cuboidal,  columnar  or 
hobnail eosinophilic cells are characteristically seen. Lesions containing 
small  tubules  are  the  one  which  commonly  leads  to  confusion  with 
prostatic  adenocarcinoma.  This  is  further  complicated  by  frequent 
negative staining reaction with basal cell markers, positive for AMACR, 
PSA  and/or  PAP  by  IHC.  PAX2  and/or  PAX8  are  newly  described 
specific  markers  for  NA  and  is  useful  in  arriving  at  the  correct 
diagnosis42.
REACTIVE ATYPIA OF LARGE GLANDS
In  the  situation  of  concurrent  inflammation,  ischemia  and 
radiation43 medium to  large    sized  glands  may  show reactive  atypia 
which may lead to distortion of the glands and nuclear atypia that can 
cause  confusion  with  prostatic  intraepithelial  neoplasia  (PIN)  and 
Gleasons large gland patterns of adenocarcinoma. The nuclei of reactive 
atypia may appear hyperchromatic but exhibits degenerative changes. In 
some  cases  prominent  nucleoli  is  seen  causing  more  confusion  with 
adenocarcinoma.
The  features  which  are  most  helpful  in  differentiating  reactive 
atypia from malignancy are the detection of the associated findings such 
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as inflammation, infarction or radiation and the existence of the basal cell 
compartment confirmed by the 34βE12 stain.
MALAKOPLAKIA
Malakoplakia of the prostate gland is featured by diffuse sheets of 
histiocytic  infiltration,  admixed  with  lymphocytes,  plasma  cells  and 
neutrophils44,45.  The  von-Hanseman histiocytes  which  is  predominantly 
seen in the early stage of malakoplakia may mimic carcinoma.
The  most  useful  features  to  distinguish  malakoplakia  from 
malignancy are   lack of acinar differentiation , presence of inflammatory 
cells  and  typical  Michaelis–Gutmann   bodies.  In  difficult  cases 
immunohistochemistry is needed which is characterised by the presence 
of CD68 and lack of cytokeratins and prostatic epithelial makers.
XANTHOMA
Prostatic  xanthoma is  another  benign mimicking lesion of  high-
grade prostatic adenocarcinoma or hormonally treated prostatic cancer. 
Chuang, Ai-Ying; Epstein, Jonathan I. studied the cases  from 1995 to 
2006,  at  The  Johns  Hopkin Hospital, USA46.  Xanthoma was noted on 
needle biopsy in 25 cases with 2 cases observed on TURP specimens, 
The  cells  of  xanthoma  had  uniform,  benign-nuclei,  inconspicuous 
nucleoli  and  abundant  foamy  cytoplasm.  No  mitotic  figures  were 
identified. Focal areas of necrosis  was seen in 1 case. The predominant 
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pattern  observed  is  the  well  circumscribed  solid  nodular  pattern 
(17cases).  Ten  cases  showed  a  pattern  of  cords  and  individual  cells 
infiltrating the stroma, further simulating high-grade prostate carcinoma. 
A mixture of these two patterns is observed in two cases. IHC is done in 
19 cases which had sufficient tissue. CD68 was strongly positive in 18 
cases (94.7%) and CAM5.2 was positive in none of the cases (0%). 2of 
17  (11.8%)  cases  1of  15  (6.7%),  and 1  out  of  12  (8.3%)  cases  were 
positive for, prostate-specific acid phosphatase prostate-specific antigen, 
and [alpha]-methylacyl-CoA racemase, respectively.
Meticulous morphological examination and proper use of CD 68 
and CAM5.2 immunohistochemical stains are benificial in the diagnosis 
of prostatic xanthoma, chiefly in complicated cases with an infiltrative 
pattern.
Familiarity  with  the  differential  diagnosis  of  prostatic 
adenocarcinoma  is  important  in  the  situation  of  diagnosing  minimal 
adenocarcinoma in small biopsy samples. It is essential to be aware of 
those conditions which may lead to false-positive cancer diagnosis and 
the  role  of  various  immunohistichemical  markers  in  arriving  correct 
diagnosis.
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BENIGN  MIMICKERS  OF  ADENOCARCINOMA:  USEFUL 
IMMUNO 
HISTO CHEMICAL MARKERS
• Cytokeratins(general)
AE1/AE3, CAM 5.2, MAK6
• Basal cell markers
               34βE12, CK5/6, p63
• Secretory cell marker
               Prostate-specific antigen (PSA), 
               Prostatic acid phosphatase (PAP),
               CD57
• Neuroendocrine markers
              Chromogranin, synaptophysin
• Lymphohistiocytic markers
              Leukocyte common antigen, CD56, CD68
• Other markers
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              a-Methylacyl-CoA racemase (P504S).
Basal Cell–Associated Markers
In invasive prostate carcinoma, the basal cell layer is absent, so a 
complete  absence  of  staining  in  basal  cell–  associated  markers  is 
supportive  of  malignant  diagnosis.  Under  hematoxylin-eosin  (H&E) 
microscopy,  basal  cells  may  be  mimicked  by  prostatic  stromal  cells 
juxtaposed to the glandular-basement membrane, by endothelial cells of 
blood  vessels  closely  situated  to  acini,  and  by  tangentially  sectioned 
neoplastic  cells.  Basal  cell–associated  markers  highlight  basal  cells 
present in benign prostate glands and related benign, but architecturally 
atypical proliferations.
High- Molecular- Weight Cytokeratin 34βE12.
Highmolecular-weight  cytokeratin  (HMWCK)  34βE12  is  a 
cytoplasmic  marker  that  highlights  intermediate  cytokeratin  (CK) 
filaments in basal cells and is specific for basal cells in the prostate. The 
monoclonal  antibody  clone  34βE12  (also  known  as  CK903),  which 
targets  CK1,  CK5,  CK10,  and  CK14,  is  the  time-honored  basal  cell 
marker  used  since  198547.   Although  extended  formalin  fixation  may 
affect  34βE12 antigenicity,  it  can usually  be restored with appropriate 
antigen-retrieval techniques. This was the first prostatic marker available 
for the differential diagnosis of cancer versus atypical benign glands.
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CK 5/6.  
Another  HMWCK is  CK5/6.  The  overall  sensitivity,  specificity 
and diagnostic utility of CK5/6 in prostate needle biopsies are similar to 
34βE12.
p63
This antibody targets the nuclear protein p63 which is homologous 
to the  TP53 tumor suppressor gene and has been proven to selectively 
stain the basal cell nuclei50. P63 is comparable to HMWCK in sensitivity 
and specificity in needle biopsies,  but they have better sensitivity than 
34βE12 in transurethral resection specimens. This difference in staining 
may  be  related  to  alterations  in  antigenicity  of  basal  cells  in  benign 
prostatic hyperplasia.
p63  immunostaining  provides  greater  specificity  because  of  its 
nuclear  localization  than  the  cytoplasmic  staining  of  HMCK  markers 
which may have greater potential for nonspecific reaction.
Recommended Interpretation Guidelines.
If basal cell-layer–associated makers alone are used, the diagnosis 
of  carcinoma  is  made  on  a  negative  immunoreaction  and  therefore, 
appropriate external and internal positive and negative controls must be 
used  while interpreting  the  stain.  Before  evaluation  of  the 
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immunohistochemical slide, all morphologically atypical glands must be 
identified in H&E sections and the corresponding glands in the suspicious 
focus  should  be  completely  negative  by  immunohistochemistry.  The 
consistency  of  the  staining  reaction  should  be  confirmed  in  a  second 
section on the same slide, if available.
Potential Diagnostic Pitfalls.
Pitfalls in staining with basal cell–associated markers may be due 
to  false  negativity  in  benign  mimics  or  false  positivity  in  carcinoma. 
False negative staining in scattered, obviously benign glands is observed 
in 5% to 23% of cases. Staining may be weak-reactive to nonreactive in 
some benign proliferations that mimic cancer such as in up to 23% of 
glandular  atrophy,  up  to  50%  of  atypical  adenomatous  hyperplasia 
(AAH;adenosis) and 23% of   post–atrophic hyperplasia.
Completely negative staining can occur in non prostatic mimickers 
of carcinoma such as in 44% to 75% of nephrogenic adenoma and 66% of 
mesonephric glandular hyperplasia.
There are rare scenarios in which prostate carcinoma may show 
immunoreactivity with basal cell markers, for instance, entrapped benign 
gland  within  carcinoma,  cancerization  of  benign  glands,  intraductal 
cancer  growth,  ductal  carcinoma  of  prostate  and  high-grade  prostatic 
carcinoma (especially at metastatic sites).
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Epithelial Markers  
The cocktail of AE1 and AE3 detects acidic (CK10, CK14–16, and 
CK19)  and  basic  (CK1–CK6 and  CK8)  cytokeratins  and  is  the  most 
universally used epithelial marker. Cytokeratin AE1/AE3 is useful in the 
differential diagnosisof nonspecific granulomatous prostatitis, xanthoma 
cells versus high-grade prostate cancer with an infiltrative individual cell 
pattern.  Cytokeratin  AE1/AE3 is  also helpful  in  diagnosing small  cell 
proliferations involving the prostate (differential diagnosis for small cell 
carcinoma, lymphoma, and rhabdomyosarcoma).
In the post treatment  setting CK AE1/AE3is superior to PSA in 
highlighting individual atrophic prostate cancer cells52 because PSA can 
be  suppressed  by  therapy  and  is,  therefore,  not  detectable 
immunohistochemically following treatment.
Prostate Lineage–Specific Markers
Within  the  prostate  gland,  PSA  and  prostate-specific acid 
phosphatase (PSAP)  are used to confirm the prostatic acinar cell origin 
and are useful  in  ruling  out   nonprostatic carcinoma mimics  such as 
seminal  vesicle/ejaculatory duct,  hyperplastic  mesonephric  glands, 
nephrogenic adenoma, Cowper glands, and paraganglionic tissue.53 
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Another recent  immunohistochemical  marker  for  this  purpose  is 
prostate-specific membrane antigen, but there are few studies to date with 
this antibody54.
Another  use  of  PSA and  PSAP  is  in  the  diagnosis  of  unusual 
variants of  prostate  carcinoma  (ie,  ductal,  mucinous,  and  signet ring 
carcinoma),  which stain  positive for  PSA and PSAP versus secondary 
tumors  involving  the  prostate (such  as  bladder  or  colonic 
adenocarcinomas) which are typically negative.
Potential Diagnostic Pitfalls.
In  poorly  differentiated  prostate  carcinoma,  Prostate-specific 
antigen expression can be weak and focal. The polyclonal PSA antibody 
when compared to monoclonal antibody may show occasional reactivity 
in up to 32% of normal, seminal vesicles. Another condition which shows 
PSA and PSAP positivity is nephrogenic adenoma.
Prostate Cancer–Associated Marker AMACR (P504S)
The P504S gene was identified by combination of complementary 
DNA subtraction and high-throughput microarray to be over expressed 
selectively  by  malignant,  but  not  by  benign,  prostatic  glands55,56.  The 
subsequent  studies from radical  prostatectomies,  transurethral resection 
of  prostate  and  needle  biopsy  specimens  confirmed  the  selective 
immunoreactivity in malignant, but not in benign glands. 
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The  prostate  carcinoma–associated  AMACR,  if  used  in 
combination with basal cell markers has superior diagnostic value .The 
positive  staining  of  AMACR  complements  the  lack  of  basal  cell–
associated staining in prostate carcinoma and thus safeguards from false 
negativity associated with basal cell–related markers
Currently, an antibody cocktail of AMACR and basal cell markers 
is  available  and  is  an  efficient  diagnostic  tool  as  suggested  by  many 
studies. α-Methylacyl coA racemase is seen in 75% to 95% of prostate 
carcinomas in diagnostic material staining observed across the spectrum 
of Gleason 5 to 10 carcinoma.
Recommended Interpretation Guidelines. 
To be interpreted as positive for carcinoma,  AMACR should be 
circumferential,  strong and cytoplasmic, with a granular quality .To be 
found positive, the staining of malignant  glands must be stronger than 
adjacent  benign  acinar  glands.  Interpretation  must  always  be  in 
conjunction  with  H&E  morphology  and  preferably,  with  a  basal  cell 
stain.  If  there  is  a  lot  of  background  staining  throughout  the  biopsy, 
staining should not be interpreted. 
Potential Diagnostic Pitfalls.
Positive AMACR staining does not always indicate carcinoma, and 
negative  staining  does  not  rule  out  carcinoma.  False  negative 
immunoreactivity  to  AMACR  may  be  seen  in  5% to  25% of  typical 
prostate  carcinomas.  It  also  varies  with  specific  patterns  of  prostate 
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carcinoma and can be negative in 30% of atrophic carcinoma, 32% to 
38% of foamy gland carcinoma and 23% to 30% of pseudo hyperplastic 
carcinoma  variants.  Expression  can  be  substantially  diminished  or 
completely lost in up to 29% of prostate carcinoma following hormonal 
therapy.57 
Conversely,  reactivity  with AMACR is  seen in relatively higher 
proportions of premalignant proliferations. 56% to 100% of high-grade 
prostatic  intraepithelial  neoplasia  and  18%  of  AAH  showed  positive 
AMACR  staining  reaction  in  one  study. Gladell  P.  Paner,  Daniel  J. 
Observed a range close to50%
Occasionally,  reactivity  with  AMACR  can  be  seen  in  benign 
entities, such as in 35% to 58%  of nephrogenic adenoma and 2% to 36% 
of typical benign glands and also in some  secondary tumors involving 
the prostate such as urothelial carcinoma  and colonic adenocarcinoma.
          The application of basal cell–associated markers, prostate cancer 
associated marker AMACR, and prostate lineage–specific markers PSA 
and PSAP provide significant, objective evidence in confirming whether 
glandular  lesions  are  benign  or  malignant  and  whether  they  are  of 
prostatic origin. 
Although  these  markers  provide  invaluable  ancillary  diagnostic 
assistance,  the  myriad  differential  diagnostic  considerations  and 
overlapping staining reactions mean that the final diagnosis must reflect 
the context and be correlated with the original H&E-derived diagnosis.
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MATERIALS AND METHODS
An analysis of 504 cases of surgically resected prostatic specimens 
referred from urology department from July 2009 to June 2011 for a two 
year  period,  has  been  carried  out  in  Institute  of  Pathology,  Madras 
Medical College, Chennai.
The histological material were derived from biopsy specimens of 
transurethral resection of prostate in 409 cases, trucut needle biopsy in 90 
cases and open prostatectomy in 5 cases. The age group of the patients 
ranged from 33-90 yrs.
Transurethral resection had been done to the patients who came to 
the urology outpatient department with complaints of urinary obstruction. 
If the patient had been clinically suspected of having carcinoma prostate 
by digital  rectal examination,  they were screened for prostatic specific 
antigen (PSA) levels in the serum. Patients with elevated PSA levels in 
the serum or clinically suspicious patients or both have been selected for 
trucut needle biopsy. Only few patients underwent transrectal ultra sound 
(TRUS) guided biopsy.
As a routine, all prostatic specimens were fixed in 10% formalin. 
The total amount of prostatic chips received per each case varied grossly. 
But in general, we received 15 to 30 gm of prostatic chips for each case 
of TURP specimen. If the total amount of resected prostatic chips could 
35
be included in four histological sections it was examined in its entirety. 
Excess tissue was sampled at the rate of one histological section per 10 
gram of resected tissue.
In most of the trucut biopsy specimens, we received only a bit of 
soft tissue measuring 0.5 to 1 cm and serial sections were taken from this. 
As  a  routine,  5  to  8  histological  sections  were  taken  from  open 
prostatectomy specimens : 2 to 3 sections from the right and left lobe and 
one to two sections from the middle lobe.
All these histological sections were stained with Haematoxylin & 
Eosin (H&E)  stain and examined. In each benign prostatic hyperplasia 
and  adenocarcinoma  case  diagnosed,  the  evaluation  was  done  for  the 
presence  of  mimickers  of  adenocarcinoma,  inflammatory  aspects, 
presence of focal acinar atrophy, metaplastic lesions, hyperplastic lesions 
and premalignant lesions. Microphotographs were taken. IHC stains were 
done wherever found necessary.
PROCEDURE OF HAEMATOXYLIN AND EOSIN STAIN:
 Dewax the sections, hydrate through graded alcohols to water.
 Remove fixation pigments if necessary.
 Stain in haematoxylin for 5 minutes.
 Wash well in running tap water until sections become `blue' for 5 
minutes.
36
 Differentiate in 1 percent acid alcohol for 2-4 sec.
 Wash well in running tap water until sections are again `blue' for 
15 to 20 minutes.
 Stain in eosin for one minute.
 Wash in tap water for 5 minutes.
 Dry and mount the slide.
CASES OF CLEAR CELL METAPLASIA ARE STAINED WITH 
PERIODIC ACID-SCHIFF.
METHOD:
1.  Dewax sections and bring to distilled water.
2. Treat with periodic acid for 5 minutes.
3.  Wash well with several changes of distilled  water.
4. Cover with Schiff’s solution for 15 minutes.
5.  Wash in running tap water 5-10 minutes.
6. Stain nuclei with Harris Hematoxylin. Differentiate as appropriate 
in acid alcohol and blueing in tap water for 5 minutes.
7. Wash in water.
8. Rinse in absolute alcohol.
9. Clear in Xylene and mount with DPX.
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IMMUNOHISTOCHEMISTRY
Cases  for  IHC were  selected  after  viewing  the  H &E sections. 
Slides were coated with chrome alum, and subjected to Antigen Retrival 
using the Microwave technique with Citrate buffer solution. Slides were 
then treated by HRP (Horse radish peroxidase) polymer technique.
HRP POLYMER TECHNIQUE
The coated slides were taken through the following steps.
1. Treatment with peroxidase block for incubation of endogenous 
peroxidase in the tissue for 20 minutes, washed in PBS buffer 
for 5 mts.
2. Applications of power block O - to block non specific antigen 
antibody reactions for 20 minutes. The excess power block was 
blot dried.
3. Applications of Primary antibody – Murine antibodies for 60 
minutes. Washed  in PBS buffer for 5 minutes.
4. Application of super enhancer for 30 minutes which increased 
the sensitivity of antigen -antibody reaction thereby enhancing 
the final  reaction product.
38
5. Application of SS label – Secondary antibody from goat with 
the  tagged   horse  radish  peroxidase  enzyme  for  30  minutes. 
Washed in TRIS buffer.
6. Application  of  DAB  (Diamino  benzidine)  Chromogen  for  5 
minutes –which was cleared by the enzyme to give the colored 
product  at  antigen  sites.   Washed  in  distilled  water  for  5 
minutes.
7. The slides were then counter stained with hematoxylin . Slides 
were air dried and mounted with DPX (Dibutylphalate Xylene). 
The following IHC markers were done.
HMWCK  (34βE12),  CK  5/6,  Prostate  specific  antigen  (PSA), 
vimentin and CD68.                             
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OBSERVATION AND RESULTS
Out of 504 cases analysed, 409 were TURP specimens, 90 were 
trucut needle biopsies and 5 were open prostatectomy specimens.
DISTRIBUTION  OF  CASES  IN  RELATION  TO  SURGICAL 
BIOPSY SPECIMENS
TABLE - 1
Surgical biopsy 
specimens
Total No. Of cases Percentage
Transurethral resection 
of prostate
409 81.15
Trucut needle biopsy 90 17.86
Open prostatectomy 5 0.99
 Chart-1: Distribution of cases in relation to surgical biopsy specimen
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 DISTRIBUTION OF CASES BASED ON HPE DIAGNOSIS
TABLE - 2
Lesions Total no. of cases TURP
Trucut 
biopsy
Open 
prostatectomy
BPH 448 (89%) 397(97%) 47(52%) 4 (80%)
Adenocarcinom
a
44(9%) 9(2%) 34(37%) 1(20%)
Unsatisfactory 
specimen
12(2%) 3(1%) 3(1%) ---
In total about 448 cases of BPH and 44 cases of adenocarcinoma 
have  been  diagnosed  in  this  two  years  period.12  cases  turned  to  be 
unsatisfactory  specimen.  This  includes  inadequate  tissue,  poorly 
preserved specimens and biopsy from non representative sites. (Table 2)
          Chart-2: Distribuion of cases in relation to HPE diagnosis
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DISTRIBUTION OF CASES IN RELATION TO AGE. 
TABLE - 3
Age group No.of cases Percentage
31-40 6 1.21%
41-50 32 6.5%
51-60 130 26.4%
61-70 202 41.05%
71-80 106 21.54%
81-90 16 3.25%
      
                    Chart-3:  Distribution of cases in relation to age
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Out of 492 cases that had been reported, majority (41%) of cases 
occurred in the age group of 61-70.
Totally 134 mimickers were identified with benign lesions being 
the  commonest  (79%)  and  premalignant  lesions  mimicking 
adenocarcinoma were (21%).
DISTRIBUTION OF MIMICKERS:
TABLE - 4
Total Benign Malignant
134 106(79%) 28(21%)
  
DISTRIBTION OF IDENTIFIED BENIGN MIMICKERS:
TABLE - 5
Mimickers No.of cases Percentage
1.Basal cell hyperplasia 48 45.3
2.Atrophy simple &cystic 24 22.6
small acinar 10 9.43
3.Clear cell cribriform hyperplasia 2 1.9
4.Sclerosing adenosis 4 3.8
5.Stromal clear cell metaplasia 14 13.2
6.Xantho granulomatous prostatitis 4 3.8
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                          Chart-4: Distribution of mimickers
   
48
34
2
4
14
4
BCH
Atrophy
CCCH
SA
Stromal ccm
XGP
                        Chart-5: Distribution of benign mimickers
Among  benign  mimickers  BCH  was  the  commonest  (45%) 
followed by atrophy (32%).
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Totally  48 foci  of  basal  cell  hyperplasia  were found in the 504 
surgically  resected  specimens  (9.52%).  26  were  partial   basal  cell 
hyperplasia,  9  were complete  basal  cell  hyperplasia,  1  was  cribriform 
BCH and 12 were atypical basal cell hyperplasia.Out of 48 foci 47 were 
seen in association with benign prostatic hyperplasia and one was seen in 
the backdrop of adenocarcinoma.
TYPES OF BASAL CELL HYPERPLASIA:
TABLE -  6
Types No. Of cases Percntage
Partial (Glandular) 26 54
Complete (Solid) 9 19
Cribriform 1 2
Atypical (with prominent 
nucleoli)
12 25
PREMALIGNANT LESIONS
Atypical  small  acinar  proliferation  and  PIN  are  the  two 
premalignant  mimickers  identified  in  this  study.  Both of  these  lesions 
were  commonly  seen  in  association  with  adenocarcinoma  rather  than 
BPH.
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PREMALIGNANT MIMICKERS :
TABLE - 7
Premalignant 
mimicker
No. Of cases Percentage
AAH/ASAP 22 78.6
PIN 6 21.4
                               Chart-6: Identified premalignant lesions
ASSOCIATED CONDITIONS IN PREMALIGNANT MIMICKERS 
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TABLE - 8
HPE Diagnosis
Premalignant lesions
AAH/ASAP PIN
BPH 20 (4.46%) 5 (1.11%)
Adenocarcinoma 2 (4.54%) 1(2.27%)
ASSOCIATED CONDITIONS IN MIMICKERS
TABLE  - 9
BPH Adenocarcinoma
Mimicker
s
Benign(106)
105 (23.4%) 1 (2.3%)
Premalignant 
(28)
25 (5.6%) 3 (6.8%)
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                      Chart-7: Associated conditions in mimickers
Out  of  106  benign  mimickers  identified  105  were  seen  in 
association with benign prostatic hyperplasia and only one case was seen 
in the setting of adenocarcinoma. Premalignant mimickers are found in 
both BPH and in adenocarcinoma but majority wer seen in association 
with adenocarcinoma.  
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IHC IN EACH GROUP OF BENIGN MIMICKERS: 
TABLE - 10
Mim
icker
total 
no.of 
cases
IHC 
Done
34βE12 CK5/6 Vimentin CD68 PSA
total +ve total +ve total +ve total +ve total +ve
BCH 48 12 12 12 12 12 - - -
SAA 10 10 10 9 10 9 - - -
CCC
H
2 2 2 2 2 2 - - -
Stro
mal 
CCM
14 14 14 14 14 - 14 11 14 1 2 2
XGP 4 4 4 4 4 4 4 2 4 2 - -
SA 4 4 4 4 4 4 - - -
 
 Immunohistochemical staining with 34βE12 and CK5/6 was done 
in 46 cases of benign mimickers.  Out of which 45 showed continuous 
staining of  the basal  cell  layer.  A single  case of  small  acinar  atrophy 
showed absence of basal layer. Staining with vimentin and CD 68 was 
done in 18 cases. Out of which 13 were positive for vimentin and 3 were 
positive for CD68.The remaining two cases which were negative for both 
vimentin  and CD68 were further stained with PSA and the clear  cells 
showed positive reaction with PSA.
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IHC IN PREMALIGNANT MIMICKERS
Mimicker
Total 
no.of.case
IHC 
done
34ΒE12 & CK 5/6 PSA
+veContinuous discontinuous negative
ASAP 22 16 1 14 1 15
PIN 6 6 3 3 - 6
  
In 28 cases of premalignant mimickers IHC was done in 22 cases 
which  includes 16 cases of ASAP and 6 cases of PIN. Out of 16 ASAP 
cases  14  cases  showed  discontinuous  staining  pattern  of  basal  cells, 
continuous  staining  pattern  was  observed  in  one  case  and  one  case 
showed no staining of basal cells. In 6 PIN cases, continuous staining of 
basal cells was seen in 3 cases and another 3 cases showed discontinuous 
staining pattern. Out of 22 cases stained with PSA except for one case all 
other showed positive staining reaction. 
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DISCUSSION
Prostatic carcinoma and benign prostatic hyperplasia are the two 
principal conditions to involve the prostate. They account for more than 
90% of all prostatic disease.
In  general,  the  morphological  diagnosis  of  prostatic  lesions, 
particularly  separating  benign  from  malignant  lesions  is  relatively 
straightforward.  However  there  are  several  benign  proliferations  and 
normal  histoanatomic  structures of  the prostate,  which exhibit  a  small 
glandular  pattern  with  or  without  cytological  atypia,  and  they  can  be 
mistaken for malignancy if one is not aware of the morphologic nuances.
They  do  not  have  specific  clinical  manifestations  and  most 
encountered  during  examination  of  prostatic  samples  from patients  in 
whom the clinical diagnosis is BPH. The distinction between PCA and 
benign conditions is traditionally made on purely morphologic grounds, 
but  is  often problematical.  As a  result,  immunohistochemical  methods 
have been introduced in the differential diagnosis of these conditions.58,59.
Preservation of the prostate gland's two-cell-layer structure (inner 
glandular  epithelium  and  outer  basal  cells)  is  a  reliable  criterion  for 
benign  glandular  proliferation.  Because  the  two-cell-layer  structure  in 
benign  proliferative  lesions  is  often  not  discernible  on  purely 
morphologic grounds in hematoxylin and eosin-stained (H&E) sections, 
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differential diagnosis could benefit from detection of outer basal cells by 
immunohistochemical  methods  that  employ  34βE12,  directed  against 
high molecular weight  cytokeratin, as the primary antibody60,61. Several 
investigators have recently reported the usefulness of this method.62,63.  
Out of 504cases analyzed in our study benign prostatic hyperplasia 
were found in 448 (89%) patients, prostatic adenocarcinoma in 44 (9%) 
patients and 12 (2%) specimens turned out to be inadequate samples for 
making a diagnosis. The patients were in the age group ranging from 33to 
90 years.
Totally 134 mimickers were identified. Out of these lesions benign 
mimickers  were  106  and  premalignant  mimickers  were  28.  Benign 
mimickers  were  almost  always  witnessed  in  association  with  benign 
prostatic hyperplasia, whereas premalignant lesions are commonly seen 
in association with adenocarcinoma rather than BPH.
 Basal  cell  hyperplasia is  the commonest  benign lesion identified 
(9.52%) in our study. Majority of them are seen in TURP specimens and 
only 6 cases are noticed in needle biopsy specimens.
Phatarapon  Thorson  et  al.64 studied  the  occurence  of  basal  cell 
hyperplasia  in  peripheral  zone  using  500  consecutive  needle  biopsy 
specimen and found the incidence to be 10.2%. In our study 90 trucut 
needle biopsies were examined and BCH were found in 6 cases which is 
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6.66%. This finding has diagnostic value because basal cell hyperplasia, 
especially  atypical  basal  cell  hyperplasia,  can  simulate  high-grade 
prostatic  intraepithelial  neoplasia  and  adenocarcinoma  particularly  in 
needle biopsy specimen65  .  In one study66   26% of cases  of basal cell 
hyperplasia were misdiagnosed as adenocarcinoma .
In  our study 12 cases  of  atypical  BCH with prominent 
nucleoli was identified. Many entities come into  the differential 
diagnosis  of  basal  cell  hyperplasia  containing prominent  nucleoli.  The 
features  help  to  discriminate  basal  cell  hyperplasia  with  prominent 
nucleoli from high grade prostatic intraepithelial neoplasia, includes the 
nodular architecture, the presence of  atypical basal cells beneath benign 
secretory  nuclei,  solid  nests,  smaller  glands  absence  of  PSA 
immunoreactivity  in  the  atypical  basal  cells  and the  evidence  of  high 
molecular weight cytokeratin immunoreactivity.
We confirmed the existence of basal cells  in all  of our cases of 
atypical  basal  cell  hyperplasia,  with  the  help  of  34βE12  and  CK5/6 
immunohistochemical staining. We had one case of cribriform basal 
cell  hyperplasia.  Cribriform  basal  cell  hyperplasia  may  be 
misdiagnosed as cribriform pattern of  PIN or carcinoma. However the 
bland  nature  of   basaloid  cells  in  high  power  magnifications  help  in 
diagnosis.
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Other   prostatic basal cell proliferative conditions that should be in 
differential diagnostic checklist comprise basal cell adenoma, basal cell 
carcinoma,  adenoid  basal  cell  tumor,   adenoid  cystic-like  tumor  and 
adenoid cystic carcinoma, and. Use of proliferative markers such as bcl-2 
and Ki-67 immunomarkers can help to distinguish basal cell hyperplasia 
from the basaloid carcinomas that  rarely occurs in the prostate67 .
There is no proof till  date to suggest that basal cell hyperplasia, 
with or without nucleoli,  is  a  precursor lesion for  high-grade prostatic 
intraepithelial neoplasia or carcinoma .68
ATROPHY          
Mahul B. Amin et al.69 stated that the most commonly encountered 
pattern simulating the microacinar architecture of carcinoma is atrophy. A 
less common glandular  pattern that forms one part  of the spectrum of 
atrophy is postatrophic hyperplasia, a lesion that has attained a renewed 
attention in the recent past in the literature.
Recently, Herawi et al.70  showed that partial atrophy is one of the 
common benign lesion which mimics adenocarcinoma in needle biopsy 
specimens in a consultation service at an academic institution.
In  our  study totally  34  atrophic  foci  were  identified  of  which 
simple and cystic atrophy contributed to 24 cases and remaining 10 cases 
were small acinar atrophy/ partial atrophy.
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Regardless of the architectural subtype the cytological features of 
atrophy are similar.  The cells are small,  dark and shrunken. They had 
increasd  nuclear  cytoplasmic  ratios  but  had regular  nuclear  membrane 
without  any  identifiable  chromatin  abnormalities.  Double  layering  of 
cells is regularly seen but in some cases it was difficult to appreciate due 
to marked atrophy of secretory cells.
In our study 10 cases of small acinar atrophy were identified, stains 
for  high molecular  weight keratin (34βE12) and CK5/6 are utilized to 
highlight the basal  cells.  Out of 10 cases 9 showed presence of intact 
basal cell layer and one case was negative suggesting malignant nature of 
the glands and it was further stained with PSA to confirm.
But studies shows that complete negativity for basal cell markers in 
atrophic glands can be seen upto 23% of cases.  Less number of basal 
cells  in  individual  glands  also  leads  to  disrupted  staining  pattern.70 
Additionally  atrophic  glands  may  also  stain  positive  with  AMACR 
(p504S), a prostate cancer specific antigen.
Therefore, one must  use caution when interpreting AMACR and 
basal  cell  stains  in  small  foci  of  atrophic  glands  in   needle  biopsy 
specimens.   It is essential to compare AMACR immunostaining with that 
of adjacent benign  glands in conjunction with recognition of histologic 
features of partial atrophy.
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Based on previous studies and the present study, partial  atrophy 
resembles adenocarcinoma in the following ways:
1. crowded, sometimes disordered architecture, often with individual 
appearing cells because of tangential sections of angulated glands.
2. Pale glands with more cytoplasm than in complete atrophy
3. Occasional  larger  nuclei  and  more  prominent  nucleoli  than  in 
benign  glands
4. Patchy basal cells with focal absence of basal cells on sections; and
5. Perineural indentation (pseudo–nerve invasion).
6. Negative basal cell staining and positive AMACR staining in some 
cases.
SCLEROSING ADENOSIS
In this study 4 cases of sclerosing adenosis were identified with an 
incidence of 1%. Sakamoto et al.71 reviewed sections of prostate from 263 
patients  and found 5 cases of sclerosing adenosis, with an incidence of 
1.9%.
Sclerosing adenosis is largely restricted to transition zone and is 
incidental finding in TURP and prostatectomy specimens. Its occurrence 
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in needle biopsy is extremely rare. In our study all the 4 cases are seen in 
TURP specimen.
The diagnostic difficulties of sclerosing adenosis of prostate have 
been  recognized,  and  a  recent  series  on  over  diagnosis  of  prostatic 
adenocarcinoma showed that 2% of stage T1a prostatic carcinomas were 
in fact cases of sclerosing adenosis prostate.66
Microscopically,  the  lesion  can  be  partially  well  circumscribed, 
and  the  margins  resemble  an  infiltrative  lesion,  but  the  stroma  is 
distinctive; usually it is cellular and myxoid with no smooth muscle cells 
present. Other features of diagnostic importance include the finding of a 
double  cell  population  of  clear  secretory  and amphophilic  basal  cells, 
sometimes presenting as fusiform cells infiltrating the stroma. Nucleoli 
are readily identifiable in foci of SAP, but not in the size and extent of 
prostatic carcinoma. In most cases, applying these criteria is enough to 
arrive at the diagnosis of SAP.
Pathologic  diagnosis  can  be  confirmed  by  using  a  panel  of 
immunohistochemical  markers,  which  includes  high-molecular-weight 
cytokeratin,  muscle-specific  actin  and S100 protein.  The  characteristic 
expression  of  high-molecular-weight  cytokeratin  is  diagnostic  and 
demonstrates  the presence  of  an intact  basal  layer  in  the acini  and in 
fusiform cells  infiltrating the stroma as solid  nests  and cords.  4 cases 
identified  in  this  study  are  subjected  to  staining  with  high-molecular-
57
weight cytokeratin and they demonstrated the presence of an intact basal 
layer in the acini.
CLEAR CELL CRIBRIFORM HYPERPLASIA
Benign nodular hyperplasia sometimes shows areas of prominent 
cribriform glands.  It  is  characterized  by  complex  papillary  cribriform 
hyperplasia of clear cells involving the acini of BPH. This lesion usually 
has a nodular appearance in low power with intervening cellular stroma.
The cells comprising the central cribriform areas are cuboidal to 
columnar  cells  with  uniform  nuclei  and  clear  cytoplasm.  They  lack 
nuclear  atypia  and  nucleomegaly.  Basal  cells  are  significantly  seen 
around the periphery. CCCH should not be mistaken for a carcinoma or 
paraneoplastic  condition  of  the  prostate  with  a  papillary  cribriform 
pattern. The key to the diagnosis of CCCH is the combination of bland 
cytological  features  and architectural  uniformity  in  H&E sections  and 
presence of basal cells highlighted by HMWCK stains.
Two cases of  CCCH is noted in our study and the existence of 
basal cells is confirmed by 34βE12 staining.     
STROMAL CLEAR CELL METAPLASIA
Clear  cells  in  the  stroma  of  prostate  can  be  of  stromal  origin, 
histiocytic origin or may be   malignant signet ring cells. It is important to 
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identify the origin of the clear cells, because it can cause confusion with 
the foamy gland   variant of prostatic adenocarcinoma or, if occuring as 
individual  cells,  with  grade  5  adenocarcinoma  or  signet  ring  cell 
carcinoma which is a rare variant and has worst prognosis.72
        Degeneration of lymphocytes and stromal cells can give rise to a 
signet  ring-  like morphology.73,74.   When the change is prominent,  the 
pattern  can  simulate  high-grade  adenocarcinoma  containing  individual 
signet ring cells. One should be aware of this possibility and not to over 
interpret such cells as malignant. In difficult cases, immunohistochemical 
stains can be used to verify the cell’s nonepithelial nature.
        Signet ring cell carcinoma  is a very rare entity in prostate. It is seen 
more  frequently  as a minor component of a high grade adenocarcinoma. 
SRPC in its pure form is extremely rare. The diagnosis is made when 
there are at least 25% of typical cells75,76.  
         In this study 14 cases are identified as stromal clear cell metaplasia 
in H&E sections. Immunohistochemical study using  basal cell marker 
HMWCK, mesenchymal marker vimentin and histiocytic marker CD68 
and PSA was performed to confirm the origin of clear cells and to rule 
out  malignancy.  Out  of  14  cases  11  cases  reacted  with  vimentin 
confirming the H&E diagnosis of stromal origin. 1 case turned out to be 
of histiocytic origin showing positive staining for CD68. Other 2 cases 
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which were negative for both vimentin and CD68 were stained with PSA, 
showed positivity suggesting their epithelial nature
XANTHOMA
     Xanthoma of prostate is a rare condition characterised by collection of 
lipid-laden  macrophages  in  the  prostate. Besides  being  a  histologic 
mimicker of carcinoma, It is  also a clinical mimicker because it is often 
associated  with  unusual  digital  rectal  examination77  finding  and 
abnormally elevated serum PSA levels78. 
Xanthomatous  histiocytes  usually  have  small  nuclei  with 
inconspicuous nucleoli and are admixed with other inflammatory cells. 
Only foam cells is seen in some instances which can lead to significant 
diagnostic confusion. Hypernephroid  carcinomas  which has foam cells 
similar to that of xanthomatous cell sometimes do not have the typical 
malignant nuclear features complicating the problem further.
The presence of other inflammatory cells assist in diagnosis. IHC 
for cytokeratin AMACR and CD68 is often required to solve problematic 
cases. Xanthomas are CD68 positive  and cytokeratin , AMACR and PSA 
negative.
In  our  study,   out  of  4  cases  initially  labelled  as 
xanthogranulomatous prostatitis , 2 cases retained their initial diagnosis 
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after IHC in which the clear cells have taken CD68.The clear cells in the 
other 2 cases stained positive for vimentin and not stained with CD68 
suggesting their origin from stromal cells.
PREMALIGNANT LESIONS.
Atypical  adenomatous  hyperplasia/atypical  small  acinar 
proliferation  is  a  generally  well  defined  lesion  characterised  by 
proliferation of small glands in the prostate. The incidence is reported as 
1.6- 36.9%. They are most commonly spotted  in the transition zone.
The  importance  of  ASAP  lies  in  its  potential  for  being 
misinterpreted  as  adenocarcinoma  and  various  benign  mimics such  as 
simple  lobular  atrophy,  post  atrophic  hyperplasia,  sclerosing  atrophy, 
basal cell hyperplasia and verumontanum mucosal gland hyperplasia . 
The low-power architecture is indicative of Gleason patterns 1 and 
2 adenocarcinoma. Individual glands are packed close together but not 
fused. They exhibit some discrepancy in size and shape and are lined by 
cuboidal to columnar cells having moderate to abundant clear cytoplasm. 
Basal cells are noted at least focally. 
They  have  irregular  and  somewhat  serrated  luminal  borders  in 
contrast  to  the  rigid  borders  present  in  small  acinar  carcinoma.  The 
lumens are empty but may contain corpora amylacea sometimes .   A 
fibroblastic stromal response is identified  in some instances which can be 
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mistaken for sclerosing adenosis. Nucleolar size is invariably smaller in 
atypical adenomatous hyperplasia than adenocarcinoma. This is identified 
as a transition between normal prostate epithelium and well differentiated 
adenocarcinoma usually seen in the transitional zone.
Similar  to  high-grade  PIN,  ASAP holds  a  significant  predictive 
value for cancer in repeat biopsy specimens. In studies published between 
1997 and 2001, the reported incidence of  prostate cancer in repeat biopsy 
specimens following a diagnosis of ASAP  ranged from 34% to 60%.79,80
There  are  two  potential  reasons  for  performing 
immunohistochemistry in the ASAP setting: to obtain further evidence of 
carcinoma, and to rule out potential mimics. The key immunostains for 
this  scenario  are  basal  cell  associated  markers  and  AMACR  used 
separately  or  in  a  cocktail.  In  our  study  totally  22  cases  of  ASAP is 
identified  and  IHC was  done  in  16  cases.  Among  these  16  cases  14 
showed  discontinuity  in  basal  cell  layer  when  stained  with  HMWCK 
antibody  supporting  the  original  H&E  diagnosis.  One  case  showed 
absence of basal cell layer completely suggesting malignancy. The cells 
of proliferating  glands in one case stained continuosly with HMWCK 
and was negative for PSA suggesting basal cell hyperplasia, a common 
benign  mimicker  of  ASAP.  Although  immunohistochemistry  provides 
discriminatory  staining  patterns  between  benign  and  malignant 
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conditions,  the  final  interpretation  must  be  morphologic,  using 
appropriate staining with internal and external controls.
PROSTATIC INTRAEPITHELIAL NEOPLASIA
Prostatic  intraepithelial  neoplasia  is  defined  as  architecturally 
benign ducts and acini lined by abnormal secretory cells with changes 
similar to those in cancer, but at least a focally present basal cell layer. 
This  basal  cell  layer  should  be  demonstrable  by  basal  cell 
immunostaining.
Initially PIN was classified into three grades (Grades 1, 2 and 3) 
and later on replaced by two grade  system (low grade and high grade ). 
Currently  the term PIN refers  only  to  High grade  PIN.  HGPIN as an 
isolated  finding is  found in  2.7% to 14.2% of  needle biopsies  in  one 
study.  There  are  four  major  patterns  of  high-grade  PIN:  tufting,  , 
cribiform, micropapillary and flat81. The most common  pattern is tufting 
pattern observed in  97% of cases,  although most  cases  show multiple 
patterns. In our study all the 6 cases of PIN had tufting pattern.
The different patterns of HG-PIN carries no clinical or prognostic 
significance and their detection appears to be only of diagnostic value. 
The differential diagnosis of PIN are lobular atrophy, atypical basal cell 
hyperplasia,  postatrophic  hyperplasia,  cribriform  hyperplasia  ,  and 
changes associated with radiation , infarction, and prostatitis. The most 
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common mimic of HGPIN is atypical basal cell hyperplasia. In atypical 
basal  cell hyperplasia,  cells are stratified and have prominent nucleoli, 
but they are basally located rather than abluminal which is seen in PIN. 
PIN  is  often  overdiagnosed  as  adenocarcinoma.  A  review  of 
transurethral resection specimens in the Mayo Clinic between 1960 and 
1970  showed  that  PIN  was  often  diagnosed  as  adenocarcinoma82. 
Immunohistochemistry with antibodies 34βE12 (high molecular  weight 
keratin) and p63 may be used to demonstrate the presence of basal cells, 
recognizing that PIN has  an intact or fragmented  basal layer whereas 
cancer cells do not .
According to the study of Junqi Qian and David G Bostwick , basal 
cell layer interruption is evident in 56% of high-grade PIN, and is more 
common in acini next to carcinoma than in acini at distant site. Similar to 
the above study, our study also showed basal cell layer disruption in 3 out 
of 6 cases which is 50%.
          Thus, immunohistochemical stains for antikeratin 34βE12 may 
demonstrate  the  existence  of  basal  cells  in  a  small  focus  of  atypical 
glands,  serving  to  confirm the  diagnosis.   This  antibody  can  be  used 
effectively if one  carefully interprets the findings in combination with 
the light microscopic features.83  However, recent reports have noted that 
the  percentage  of  ambiguous  cases  can  be  reduced  significantly,  by 
68%,84  or from 5.1 to 1.0 %85 by addition of this  marker. 
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           The main importance of recognizing PIN is based on its strong 
association with prostatic carcinoma. PIN has a high predictive value as a 
marker for adenocarcinoma, and its detection in biopsy specimens of the 
prostate demands further search for concurrent invasive carcinoma.
         The predominant uses of immunohistochemical staining in the 
prostate  are  distinction  of  prostate  cancer  from  its  benign  mimics, 
distinction  from urothelial  carcinoma,  and  identification  of  metastatic 
prostate  cancer.  For  the  first  purpose,  prostate  cancer  diagnosis,  the 
dominant ancillary immunostain is high-molecular weight keratin clone 
34βE12, serving to document the absence of a basal cell layer. Keratin 
5/6 is an equivalent alternative.
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SUMMARY AND CONCLUSION
• Among all the surgical specimens received for the study period for 
two years, the most common were TURP specimens (81.15%) with 
benign prostatic   hyperplasia  (89%) constituting  the  commonest 
histological category. Adenocarcinoma were found in (9.7%) of the 
cases.  Most  of  the  adenocarcinomas   were  diagnosed  in  needle 
biopsy specimen.
• About more than 90% of the prostatic lesions studied were found in 
sixth to eighth decade.
• Benign  mimickers  were  commonly  identified  (59%)  than 
premalignant  mimickers. Benign mimickers are almost 100% seen 
in specimens of  benign prostatic hyperplasia. 
• Among the benign mimicking lesions basal  cell  hyperplasia was 
the  commonest  followed  by  atrophy.  ASAP  is  the  commonest 
premalignant lesion identified.
• Histomorphology  was  sufficient  to  diagnose  most  cases. 
Difficulties  were  faced  in  differentiating  atypical  small  acinar 
proliferation, PIN , and small acinar atrophy from adenocarcinoma 
and  in determining the origin of clear cells present in the stroma 
and epithelium and their benign  vs  malignant nature.
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• Staining  with  basal  cell  markers  34βE12  and  CK  5/6  showed 
retention of intact basal cell layer in most of the benign condition. 
Discontinuos staining pattern was observed in atypical small acinar 
proliferation and in HGPIN. No difference in staining pattern or 
intensity is seen between 34βE12 and CK5/6 .Either of the marker 
can be used.
• Immunohistochemical  staining  with  PSA,  vimentin  and  CD  68 
helped to identify the origin of clear cells i.e whether epithelial, 
stromal  or  histiocytic  origin  and  helps  to  rule  out  malignancy 
especially the clear cell variety.
• In summary IHC plays an important role in diagnosis of prostate 
cancer.  It  helps  to  differentiate  malignant  glands  from  benign 
lesions  especially  for  morphologically  equivocal  glandular 
proliferations in small biopsy. 
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MASTER CHART
S.NO HPE NO. AGE
CLINICAL 
DIAGNOSIS
SPECIME
N TYPE
HPE 
DIAGNOSIS
IHC
HMWCK 
STAINING 
PATTERN
CK 5/6 STAINING 
PATTERN VIMENTIN CD 68 PSA
1. 3897/09 50 BPH TURP simple atrophy - - - - -
2. 4473/09 70 BPH TURP simple atrophy - - - - -
3. 5477/09 70 BPH TURP partial BCH - - - - -
4. 5900/09 56 BPH TURP simple atrophy - - - - -
5. 5939/09 57 BPH TURP ASAP - - - - -
6. 7025/09 70 BPH TURP simple atrophy - - - - -
7. 7025/09 70 BPH TURP complete BCH - - - - -
8. 7160/09 50 Carcinoma TRUS 
BIOPSY
simple atrophy - - - - -
9. 7302/09 63 BPH TURP partial BCH - - - - -
10. 7775/09 70 BPH TURP complete BCH - - - - -
11. 7866/09 75 BPH TURP simple atrophy - - - - -
12. 7935/09 55 BPH TURP cystic atrophy - - - - -
13. 8174/09 51 BPH TURP complete BCH - - - - -
14. 8245/09 65 Carcinoma TRUS 
BIOPSY
simple atrophy - - - - -
15. 49/10 62 BPH TURP partial BCH - - - - -
16. 51/10 70 BPH TURP cystic atrophy - - - - -
17. 88/10 70 BPH TURP SAA continuos continuous - - -
18. 194/10 60 BPH TURP Partial BCH - - - - -
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DIAGNOSIS
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N TYPE
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HMWCK 
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CK 5/6 STAINING 
PATTERN VIMENTIN CD 68 PSA
19. 550/10 81 Carcinoma TRUCUT 
BIOPSY
simple atrophy - - - - -
20. 631/10 50 BPH TURP partial BCH - - - - -
21. 835/10 75 BPH TURP partial BCH
-
- - - -
22. 998/10 60 Carcinoma TURP simple atrophy - - - - -
23. 1044/10 65 Carcinoma TURP simple atrophy - - - - -
24. 1052/10 45 BPH TURP cystic atrophy - - - - -
25. 1218/10 84 Carcinoma TRUCUT 
BIOPSY
PIN discontinuous discontinuous - - positive
26. 1334/10 56 BPH TURP simple atrophy - - - - -
27. 1575/10 65 BPH TURP PIN continuous continuous - - positive
28. 1794/10 74 BPH TRUCUT 
BIOPSY
partial BCH
29. 1841/10 70 Carcinoma TRUCUT 
BIOPSY
simple atrophy - - - - -
30. 2447/10 60 BPH TURP partial BCH - - - - -
31. 2528/10 70 BPH TURP Cystic atrophy - - - - -
32. 2630/10 73 BPH TURP CCCH continuous continuous
33. 3043/10 63 BPH TURP atypical BCH continuous continuous - - -
34. 3043/10 63 BPH TURP XGP continuous continuous positive negative negative
35. 3117/10 64 Carcinoma TRUCUT 
BIOPSY
atypical BCH continuous continuous - - -
36. 3117/10 64 Carcinoma TRUCUT 
BIOPSY
ASAP discontinuous discontinuous - - positive
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PATTERN VIMENTIN CD 68 PSA
37. 3164/10 61 BPH TURP ASAP discontinuous discontinuous - -
positive
38. 3340/10 65 BPH TURP SAA continuous continuous - - positive
39. 3350/10 58 BPH TURP partial BCH continuous continuous - - -
40. 3477/10 57 BPH TURP ASAP discontinuous discontinuous - - positive
41. 3526/10 70 BPH TURP partial BCH - - - - -
42. 3670/10 60 BPH TURP Atypical BCH continuous continuous - -- -
43. 3672/10 70 BPH TURP Atypical BCH continuous continuous - - -
44. 3862/10 75 BPH TURP sclerosing 
adenosis
continuous continuous - - -
45. 3757/1o 65 BPH TURP SAA continuous continuous - - -
46. 3875/10 65 BPH TURP PIN discontinuous discontinuous - - positive
47. 3969/10 60 BPH TURP partial  BCH - - - - -
48. 4151/10 64 BPH TURP Atypical BCH continuous continuous - - -
49. 4453/10 67 BPH TURP Cribriform 
BCH
- - - - -
50. 4537/10 58 Carcinoma Prostatecto
my
cystic atrophy - - - - -
51. 4773/10 75 BPH TURP stromal CCM continuous continuous positive negative negative
52.
4848/10 70 carcinoma TURP partial BCH - - - - -
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53. 4851/10 60 BPH TURP ASAP discontinuous discontinuous - - positive
54. 4877/10 52 BPH TURP stromal CCM continuous continuous positive negative negative
55. 4881/10 75 BPH TURP stromal CCM continuous continuous positive negative negative
56. 4951/10 51 BPH TURP partial BCH - - - - -
57. 4953/10 57 BPH TURP partial BCH - - - - -
58. 4967/10 65 BPH TURP SAA continuous continuous - - -
59. 4968/10 62 BPH TURP atypical BCH continuous continuous - - -
60. 4968/10 62 BPH TURP stromal CCM continuous continuous positive negative negative
61. 4974/10 70 BPH TURP XGP continuous continuous positive negative negative
62. 4976/10 65 BPH TURP stromal CCM continuous continuous positive negative negative
63. 5018/10 60 BPH TURP stromal CCM continuous continuous positive negative negative
64. 5141/10 65 BPH TURP partial BCH - - - - -
65. 5142/10 60 BPH TURP XGP continuous continuous negative positive negative
66. 5346/10 70 BPH TURP stromal CCM continuous continuous positive negative negative
67. 5346/10 70 BPH TURP sclerosing 
adenosis
continuous continuous - - -
68. 5539/10 50 Carcinoma biopsy partial BCH - - - - -
69. 5577/10 70 BPH TURP stromal CCM continuous continuous positive negative negative
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70. 5626/10 50 BPH TURP atypical BCH continuous continuous - - -
71. 5669/10 60 BPH TURP XGP continuous continuous negative positive negative
72. 5669/10 60 BPH TURP sclerosing 
adenosis
continuous continuous - - -
73. 5672/10 72 BPH TURP simple atrophy
74. 5757/10 70 BPH TURP sclerosing 
adenosis
continuous continuous - - -
75. 5757/10 70 BPH TURP ASAP discontinuous discontinuos - - -
76. 5899/10 65 BPH TURP ASAP discontinuous discontinuous - - positive
77. 5959/10 55 BPH TURP atypical BCH continuous continuous - - -
78. 5969/10 62 BPH TURP complete BCH - - - - -
79. 6134/10 72 Carcinoma TRUCUT 
BIOPSY
complete BCH
80. 6722/10 64 Carcinoma TURP partial BCH - - - - -
81. 6812/10 69 carcinoma biopsy SAA continuous continuous - -- -
82. 6854/10 60 BPH TURP PIN continuous continuous - - positive
83. 6929/10 80 BPH TURP CCCH continuous continuous - - -
84. 6931/10 80 BPH TURP complete BCH - - - - -
85. 7107/10 62 BPH TURP complete BCH - - - - -
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86. 7464/10 75 BPH TURP ASAP - - - - -
87. 7647/10 62 BPH TURP cystic atrophy - - - - -
88. 7717/10 60 BPH TURP PIN discontinuous discotinuous - - positive
89. 7717/10 60 BPH TURP SAA continuous continuous - - positive
90. 7717/10 60 BPH TURP stromal CCM continuous continuous negative negative positive
91. 8157/10 64 BPH TURP ASAP - - - - -
92. 8469/10 65 carcinoma trucut 
biopsy
ASAP - - - -
93. 8540/10 66 BPH TURP ASAP discontinuos discontinuous - - -
94. 8547/10 65 BPH TURP partial BCH - - - - -
95. 8647/10 65 BPH TURP atypical BCH continuous continuous - - -
96. 8647/10 65 BPH TURP ASAP discontinuous discontinuos - - positive
97. 8988/10 60 BPH TURP SAA continuous continuous - - -
98. 9008/10 83 BPH TURP simple atrophy
99. 9115/10 67 BPH TURP ASAP - - - - -
100. 9130/10 57 BPH TURP partial BCH - - - - -
101. 9231/10 45 BPH TURP SAA continuous continuous - - -
102. 9231/10 45 BPH TURP atypical BCH continuous continuous - - -
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103. 9231/10 45 BPH TURP ASAP discontinuous discontinuous - - positive
104. 9232/10 83 BPH prostatecto
my
PIN continuous continuous - - positive
105. 9253/10 40 BPH TURP complete BCH - - - - -
106. 9338/10 57 BPH TURP complete BCH - - - - -
107. 9505/10 75 BPH TURP cystic atrophy - - - - -
108. 9507/10 60 Carcinoma TRUS 
biopsy
ASAP discontinuous discontinuous - - positive
109. 65/11 65 BPH TURP partial BCH - - - - -
110. 155/11 60 Carcinoma TURP SAA continuous continuous - - -
111. 273/11 65 Carcinoma TRUS 
biopsy
ASAP discontinuous discontinuous - - positive
112. 331/11 70 BPH TURP stromal CCM continuous continuous positive negative negative
113. 382/11 75 Carcinoma TRUS 
BIOPSY
ASAP discontinuous discontinuous - - positive
114. 392/11 47 BPH TURP atypical BCH continuous continuous - - -
115. 476/11 67 BPH TURP ASAP discontinuous discontinuous - - positive
116. 582/11 75 Carcinoma TRUS 
biopsy
ASAP discontinuous discontinuos -- - -
117. 1155/11 62 BPH TURP partial BCH - - - - -
118. 1409/11 60 BPH TURP cystic atrophy - - - - -
119. 1566/11 70 BPH TURP partial BCH - - - - -
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120. 1566/11 70 BPH TURP stromal CCM continuous continuous negative negative positive
121. 1615/11 72 BPH TURP ASAP continuous continuous - - negative
122. 1675/11 60 BPH TURP stromal CCM continuous continuous positive positive negative
123. 1712/11 60 BPH TURP partial BCH - - - - -
124. 1924/11 85 BPH TURP simple atrophy - - - - -
125. 2104/11 72 BPH TURP cyst.atrophy - - - - -
126. 2802/11 74 BPH TURP partial BCH - - - - -
127. 3027/11 68 BPH TURP ASAP discontinuous discontinuous - - positive
128. 3307/11 66 BPH TURP partial BCH - - - - -
129. 3463/11 68 carcinoma biopsy partial BCH - - - - -
130. 3692/11 63 BPH TURP SAA continuous continuous - -
131. 3692/11 63 BPH TURP stromal CCM continuous continuous negative negative positive
132. 4061/11 53 BPH TURP stromal CCM continuous continuous positive negative negative
133. 4061/11 53 BPH TURP SAA continuous continuous - - -
134. 4298/11 65 Carcinoma TRUCUT 
biopsy
ASAP discontinuous discontinuous - -- positive
Figure-1 Basal cell hyperplasia (H&E X100x)
Figure-2 Basal cell hyperplasia (H&EX100x)
Figure-7. Atypical Basal  cell hyperplasia (H&Ex400)
Figure-8. Atypical basal cell hyperplasia-HMWCK stain
       
Figure-3 Basal cellhyperplasia Figure-4 Basal cell hyperplasia
              (H&Ex100) (H&Ex400)
Figure-5: BCH-HMWCK Figure-6 BCH CK5/6
           Stain (100x)                Stain(400x)
Figure-9 Squamous metaplasia (H&EX100x)
Figure-10 Squamous metaplasia (H&E X400x)
Figure-11  Squamous metaplasia- HMWCK stain
Figure-12 Clear call hyperplasia  (H&EX100x)
Figure-13  Clear cell hyperplasia (H&Ex100x)
Figure- 14  clear cell cribriform hyperplasia (H&EX400x)
Figure-15  Simple atrophy (H&EX100x)
Figure-16:   Small acinar atiophy (H&EX100x)
Figure-17 : Small acinar atrophy-HMWCKstain
Figure-18 : Sclerosing adenosis (H&EX100x)
Figure-19: Sclerosing adenosis- HMWCK stain
Figure-20: Stromal clear cells (H&E x100x)
Figure-21: Stromal clear cells (H&EX400x)
Figure-22: Stromal clear cells –vimentin positive
Figure-23.Xanthoma-(H&Ex 100x)
Figure-24. Xanthoma :CD68 stain
Figure-25: Atypical small acinar  proliferation(H&EX100x)
Figure-26: Atypical Small acinar Proliferation
HMWCK stain-Discontinuous lining of basal cell layer
Figure-27. Atypical small acinar proliferation.(H&EX100x)
Figure-28. Atypical Small acinar Proliferation
CK 5/6 stain-Discontinuous lining of basal cell layer
Figure-29 :Prostatic intraepithelial neoplasia –Tufting pattern.
Figure-30 : PIN –Tufting pattern. (H&EX400x
Figure-31: PIN-HMWCK stain,continuous staining of basal cells
Figure-32: PIN –Discontinuous staining of basal cells 
(HMWCK)
Figure-33: Prostatic intraepithelial neoplasia-PSA stain
Figure-34 : Prostatic intraepithelial neoplasia-PSA stain(400x)
                                                              ABSTRACT
BACKGROUND: Prostatic cancer is the most common cancer in men and is 
the third leading cause of cancer death in men in USA. Early detection of cancer 
is very important and PSA serves as a useful tool for screening the patients. The 
diagnosis is however established by needle biopsy samples and occasionally in 
TURP and other  resected specimens.  They are various benign lesions which 
may  mimic  adenocarcinoma  and  they  are  basal  cell  hyperplasia,  atrophy, 
adenosis, atypical adenomatous hyperplasia and verumontanum mucosal gland 
hyperplasia.  Also  normal  structures  such  as  seminal  vesicle  and  ejaculatory 
ducts  may  show  focal  atypia  and  may  be  confused  with  adenocarcinoma. 
Premalignant lesions such as low grade and high grade PIN also have to be 
differentiated  from adenocarcinoma.  They  may  pose  diagnostic  dilemmas  in 
small  biopsies,  so  that  the  application  of  IHC  markers  could  be  of  use  in 
distinguishing between non-neoplastic, preneoplastic and neoplastic lesions.
AIMS:  To  study  the  histopathological  features  of  mimics  of  prostatic 
adenocarcinoma,  to  differentiate  histopathologically  between  mimics  and 
adenocarcinoma  and  to  define  the  role  of  immunohistochemical  markers  in 
differential diagnosis of adenocarcinoma and its mimics.
MATERIALS AND METHODS:  Clinical  data  are  collected  from patients 
consulted in department of urology and surgery for prostate lesions during the 
period of July 2009 to June 2011. The tissues are processed and histological 
features are studied. Various benign and premalignant mimickers are identified 
and IHC markers, particularly basal cell markers 34βE12and CK5/6, vimentin, 
CD68 and PSA are applied in difficult cases to differentiate from malignancy 
and to identify the origin of clear cells present in the stroma.
RESULTS: Out of 492 cases analysed 134 mimickers were identified. Benign 
mimickers  are  commonly  found  (79%) than premalignant  mimickers  (21%). 
Among benign lesions basal  cell  hyperplasia  is  the commonest  followed by 
atrophy.  Premalignant  lesions  are  commonly  seen  in  association  with 
adenocarcinoma. Retention of intact basal cell layer is seen in almost all benign 
lesions and discontinuous basal layer is observed in 3/6 PIN cases and in 14/16. 
atypical  small  acinar  proliferation  cases.  Complete  loss  of  basal  cells  is 
observed in 2/16 cases of ASAP. Origin of clear cells are confirmed using IHC 
markers. Out of 18 cases with clear cells, 13 cases stained positive for vimentin, 
3 cases are positive for PSA and 2 cases are positive for CD68.
CONCLUSION: Basal cell layer of prostate gland is retained in most of the 
benign lesions.  It  is  lost  focally  in PIN and in ASAP. Immunohistochemical 
markers are particularly useful in differentiating malignant glands from benign 
lesions  especially  for  morphologically  equivocal  glandular  proliferations  in 
small  biopsy  and  to  identify  the  origin  of  clear  cells  and helps  to  rule  out 
malignancy especially the clear cell variety.
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